Entera Bio to present data across three oral peptide programs

Entera Bio (ENTX) announced that the Company will present data across three key programs during September 2025. American Society for Bone and Mineral Research 2025 Annual Meeting: Title: Effects of EB613 Tablets on Trabecular and Cortical Bone Using 3D-DXA: Results from Phase 2 Study: EB613 is being developed as the first, once-daily oral anabolic tablet treatment for postmenopausal women with osteoporosis. A placebo-controlled Phase 2 study in 161 post-menopausal women produced a rapid onset of action with increases in BMD at both cortical bone and cancellous bone. Based on a July 2025 alignment with FDA, Entera is planning a global Phase 3 registration study of EB613 in women with osteoporosis. Poster Presentation – Next-Gen EB613 Title: Advancing Oral Anabolic Treatments for Osteoporosis: Pre-Clinical Data for Next-Gen EB613 Tablet Utilizing N-Tab Proprietary Technology. Poster Presentation – GLP-2 Short Bowel Syndrome: Title: A First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome: The oral GLP-2 tablet program combines a proprietary long acting GLP-2 agonist developed by OPKO Health with Entera’s proprietary N-Tab technology for patients suffering from short bowel syndrome and additional disorders involving gastrointestinal mucosal inflammation and nutrient malabsorption. Currently, the only approved GLP-2 agonist requires daily subcutaneous injections.